Maeda N, Satake S, Okada Y, Asahara S, Hasuike N, Tamura M, Takata M, Tasaka K, Okutani T, Maeda Y, Tomofuji Y, Chinzei T, Saigo K
Dept. of Internal Medicine, Kakogawa Municipal Hospital.
Gan To Kagaku Ryoho. 2001 Mar;28(3):407-10.
AML with trilineage myelodysplasia (AML/TMDS) is recognized as having of poor prognosis due to its resistance to chemotherapy in comparison with de novo AML. An AML/TMDS patient who failed to respond to ordinary induction therapy achieved complete remission with combination therapy consisting of all-trans retinoic acid (ATRA) and low-dose Ara-C. No serious toxicity was observed. ATRA combined with low-dose Ara-C could be an alternative treatment for this kind of patient.
伴有三系骨髓发育异常的急性髓系白血病（AML/TMDS）被认为预后较差，因为与原发性AML相比，它对化疗具有耐药性。一名对普通诱导治疗无反应的AML/TMDS患者通过全反式维甲酸（ATRA）和小剂量阿糖胞苷的联合治疗实现了完全缓解。未观察到严重毒性。ATRA联合小剂量阿糖胞苷可能是这类患者的一种替代治疗方法。
